Medication options for treatment-resistant schizophrenia: implications for global mental health financing

References

• Practice Guidelines for the Treatment of Patients with Schizophrenia. 2nd ed. Am J Psychiatry 2004;161(2 Suppl):24.
   Google Scholar
• Conley RR, Deanna LK. Management of treatment resistance in schizophrenia. Biol Psychiatry 2001; 50(11)898–911
   PubMed Web of Science ®Google Scholar
• Brenner HD, Dencker SJ, Goldstein MJ, et al. Defining treatment refractoriness in schizophrenia. Schizophr Bull 1990; 16(4)551–61
   PubMed Web of Science ®Google Scholar
• Kane J, Honigfeld G, Singer J. Clozapine for treatment resistant schizophrenia: A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789–96
   PubMed Web of Science ®Google Scholar
• Kinon B, Kane JM, Perovish R. Influence of neuroleptic dose and class in treatment-resistant schizophrenia relapse. Presented at the 32nd Annual Meeting of the New Clinical Drug Evaluation Unit, Key Biscayne, Florida; 1992.
   Google Scholar
• Smith E, Docherty JP. Standards of care and clinical algorithms for treating schizophrenia. Psychiatr Clin North Am 1998; 21: 203–20
   PubMedGoogle Scholar
• Barnes TR, McEvedy CJ. Pharmacological treatment strategies in the non-responsive schizophrenic patient. Int Clin Psychopharmacol 1996; 11(Suppl 2)67–71
   Google Scholar
• Marder R. Antipsychotic drugs and relapse prevention. Schizophr Res 1999; 35: S87–92
   PubMed Web of Science ®Google Scholar
• Miller AL, Chiles JA, Chiles JK, Crimson MD. The TMAP schizophrenia algorithms. J Clin Psychiatry 1999; 60: 649–57
   PubMed Web of Science ®Google Scholar
• Leucht S, McGrath J, Kissling W. Lithium for schizophrenia (Cochrane Review). The Cochrane Library, issue 2. Chichester: John Wiley & Sons; 2004.
   Google Scholar
• Christison GW, Kirch DG, Wyatt RJ. When symptoms persist: Choosing among alternative somatic treatments for schizophrenia. Schizophr Bull 1991; 17: 217–45
   PubMed Web of Science ®Google Scholar
• Sculz SC, Thompson PA, Jacobs M. Lithium augmentation fails to reduce symptoms in poorly responsive schizophrenic outpatients. J Clin Psychiatry 1999; 60: 366–72
   Google Scholar
• Meltzer HY, Lee M, Cola P. The evolution of treatment-resistance: biologic implications. J Clin Psychopharmacol 1998; 18: S5–11
   Web of Science ®Google Scholar
• Simhandl C, Meszaros K. The use of carbamazepine in the treatment of schizophrenia and schizoaffective psychosis: A review. J Psychiatr Neurosci 1992; 17: 1–14
   PubMed Web of Science ®Google Scholar
• Citrome L, Levine J, Allingham B. Changes in the use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiatr Serv 2000; 51: 634–8
   PubMed Web of Science ®Google Scholar
• Wassef AA, Dott SG, Harris A. Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia. J Clin Psychopharmacol 2000; 20: 357–61
   PubMed Web of Science ®Google Scholar
• Dose M, Hellweg R, Yassouridis A. Combined treatment of schizophrenic psychosis with haloperidol and valproate. Pharmacopsychiatry 1998; 31: 122–5
   PubMed Web of Science ®Google Scholar
• Dursun M, McIntosh D, Milliken H. Clozapine plus lamotrigine in treatment-resistant schizophrenia. Arch Gen Psychiatry 1999; 56: 950
   PubMed Web of Science ®Google Scholar
• Wolkowitz M, Turetsky N, Rues VI. Bezodiazepine augmentation of neuroleptics in treatment-resistant schizophrenia. Psychopharmacol Bull 1992; 28: 291–5
   PubMedGoogle Scholar
• Pato CN, Wolkowitz OM, Rapaport M. Benzodiazepine augmentation of neuroleptic treatment in patients with schizophrenia. Psychopharmacol Bull 1989; 25: 263–6
   PubMedGoogle Scholar
• Meltzer HY. New drugs for the treatment of schizophrenia. Psychiatr Clin North Am 1993; 16: 365–85
   Google Scholar
• Tharyan P, Adams CE. Electroconvulsive therapy for schizophrenia (Cochrane Review). The Cochrane Library, issue 2. Chichester: John Wiley & Sons; 2004.
   Google Scholar
• Chanpattana W, Comchai Chakrabhand ML. Combined ECT and neuroleptic therapy in treatment-refractory schizophrenia: Prediction of outcome. Psych Res 2001; 105: 107–15
   PubMed Web of Science ®Google Scholar
• Chanpattana W, Kramer BA. Acute and maintenance ECT with flupenthixol in refractory schizophrenia: Sustained improvements in psychopathology, quality of life, and social outcomes. Schizophr Res 2003; 63(1–2)189–93
   Google Scholar
• Keks NA, Altson K, Hope J. Use of antipsychotics and adjunctive medications by an inner urban community psychiatry service. Aust NZ J Psychiatry 1999; 33(6)896–901
   PubMed Web of Science ®Google Scholar
• Adesanya A, Pantelis C. Adjunctive risperidone treatment in patients with clozapine-resistant schizophrenia. Aust NZ J Psychiatry 2000; 34(3)533–4
   PubMed Web of Science ®Google Scholar
• Gupta S, Sonnenberg SJ, Frank B. Olanzapine augmentation of clozapine. Ann Clin Psychiatry 1998; 10(3)113–15
   Google Scholar
• Mowerman S, Siris SG. Adjunctive loxapine in a clozapine-resistant cohort of schizophrenic patients. Ann Clin Psychiatry 1996; 8: 193–7
   PubMedGoogle Scholar
• Shiloh R, Zemishlany Z, Aizenberg D. Sulpiride augmentationin people with schizophrenia partially responsive to clozapine: A double-blind, placebo-controlled study. Br J Psychiatry 1997; 171: 569–73
   PubMed Web of Science ®Google Scholar
• Friedman J, Ault K, Powchik P. Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine. Biol Psychiatr 1999; 42(6)522–3
   Google Scholar
• Munro JC. Poster presented at 40th Annual Meeting of American College of Neuropsychopharmacology, December 9–13 2001, Waikoloa, Hawaii.
   Google Scholar
• Lemer V, Chudakova B, Kravets S, Ployakova I. Combined use of risperidone and olanzapine in the treatment of patients with resistant schizophrenia: A preliminary case series report. Clin Neuropharmacol 2000; 23(5)284–6
   Google Scholar
• Henderson DC, Goff DC. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. Clin Psychiatry 1996; 57: 395–7
   PubMed Web of Science ®Google Scholar
• Masand P. An evidence based approach to rational polypharmacy in schizophrenia. Presented at the APA Annual Meeting, San Fransisco, 17–23 May 2003.
   Google Scholar
• Heresco-Levy U, Ermilov M, Lichtenberg P, Bar G, Javitt DC. High dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol Psychiatry 2004; 55: 165–71
   PubMed Web of Science ®Google Scholar
• Muller N, Riedel M, Scheppach C. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 2002; 159(6)1029–34
   PubMed Web of Science ®Google Scholar
• Emsley R, Oosthuizen P, Van Rensburg SJ. Clinical potential of omega-3 fatty acids in the treatment of schizophrenia. CNS Drugs 2003; 17(15)1081–91
   PubMed Web of Science ®Google Scholar
• Strous RD, Maayan R. DHEA augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Arch Gen Psychiatry 2003; 60: 133–41
   PubMed Web of Science ®Google Scholar
• Wahlbeck K, Cheine MV, Gilbody S. Efficacy of beta-blocker supplementation for schizophrenia: A systematic review of randomized trials. Schizophr Res 2000; 41(2)341–7
   Google Scholar
• Risch SC. Poster presented at 41st Annual Meeting of American College of Neuropsychopharmacology, 8–12 December, 2002, San Juan, Puerto Rico.
   Google Scholar
• Stryjer R, Strous RD, Bar F, et al. Beneficial effect of donepezil augmentation for the management of comorbid schizophrenia and dementia. Clin Neuropharmacol 2003; 26(1)12–17
   PubMed Web of Science ®Google Scholar
• Torrey EF. The release of the mentally ill from institutions: A well-intentional disaster. Chronicle Higher Educ 1997;13 June:14.
   Google Scholar
• Robin EC, Bartels SJ, Mellman TA. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: Implications for State Mental Health policy. Schizophr Bull 2002; 28(1)75–84
   Google Scholar
• Medicaid formulary policies: Access to high-cost mental health medications. November 1999. Bazelon Center for the National Institute of Mental Health, Service Systems Research Program, 5600 Fishers Lane, Rockville, MD 20857 (contract number QVP–80076): http://www.bazelon.org/issues/medicaid/publications/formulary.htm (accessed: 6/3/2004).
   Google Scholar
• Stahl SM. Editorial: Antipsychotic polypharmacy: Evidence based or eminence based?. Acta Psychiatr Scand 2002; 106: 321–2
   PubMed Web of Science ®Google Scholar
• Saxena S, Sharan P, Saraceno B. Budget and financing of mental health services: Baseline information on 89 countries from WHO's Project Atlas. J Ment Health Policy Econ 2003; 6(3)135–43
   PubMedGoogle Scholar
• Launois R, Toumi M, Reboul-Marty J, Lancon C. Cost of illness: An inextricable maze or an aid in decision making? The case of schizophrenia] [in French]. Encephale 1998; 24(2)83–99
   Google Scholar
• Castle D, Morgan V, Jablensky A. Antipsychotic use in Australia: the patients’ perspective. Aust NZ Psychiatry 2002; 36(5)633–41
   PubMed Web of Science ®Google Scholar
• McCue RE, Waheed R, Urcuyo L. Polypharmacy in patients with schizophrenia. J Clin Psychiatry 2003; 64(9)984–9
   Web of Science ®Google Scholar
• Miller AL, Hall CS, Buchanan RW, et al. The Texas Medication Algorithm Project. Antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry 2004; 65: 500–8
   PubMed Web of Science ®Google Scholar